Background {#Sec1}
==========

In recent years, a substantial number of children have been conceived using assisted reproductive technology (ART) particularly in high-income countries \[[@CR1]\]. Currently the proportion of children conceived by ART in Japan is roughly 5% \[[@CR2]\] and is rising \[[@CR2]--[@CR5]\]. However, women who conceive by ART have a higher risk of maternal and perinatal complications, such as pregnancy-induced hypertension (PIH), placenta previa, placental abruption, morbidly adherent placenta (MAP), preterm birth, and low birth weight \[[@CR6]--[@CR10]\]. Numerous studies have investigated the reasons for this higher risk without reaching any definite conclusions. Potential causes include underlying maternal characteristics which necessitated the use of ART as well as the ART itself \[[@CR10]--[@CR16]\].

Although complications related to ART pregnancies have been well studied using large-scale registry and cohort data worldwide, many of these studies have focused on outcomes in fetuses and neonates born after ART \[[@CR7]--[@CR9]\]. Less attention has been paid to adverse maternal outcomes, and only a few studies have assessed the overall risk of life-threatening conditions, such as blood transfusion, peripartum hysterectomy, intensive care unit (ICU) admission, and maternal death in this population \[[@CR15]--[@CR20]\]. In Japan, there is an online registration system which covers more than 90% of ART cycles conducted nationwide and their outcomes. Although this system collects detailed information on ART, data pertaining to maternal/perinatal complications and adverse outcomes are limited \[[@CR2]\].

To redress this omission, we conducted the present study as an adjunct to the Japan environment and children's study (JECS), a nationwide cohort study of environmental impacts on child health. The aim of the present study was to assess and compare the risk of maternal/perinatal complications and adverse outcomes between women who conceived by ART and women who conceived naturally.

Methods {#Sec2}
=======

This study was conducted as an adjunct to the JECS, an ongoing nationwide birth cohort study in Japan aiming to determine the impact of environmental factors on child health (data set: jecs-ag-20,160,424). Details of the JECS protocol have been published elsewhere \[[@CR21]\]. Briefly, JECS is being conducted in 15 regions covering a variety of regions throughout Japan. Expecting mothers were recruited either at cooperating obstetric facilities or local government offices between January 2011 and March 2014. JECS covers a total of 103,099 pregnancies and includes follow up studies of the children resulting from those pregnancies until they have reached the age of 13.

During pregnancy and at one month postpartum, various data were collected from the participants using a self-administered questionnaire. The collected information included maternal and paternal characteristics, anthropometric measurements, medical history, socio-economic status (e.g., income, occupation, and education), life-style (food consumption, exercise, and sleep), mental health, exposure to chemicals, etc. Furthermore, medical information pertaining to the pregnancy course, delivery, and postpartum condition was collected by extraction of data from the participants' medical records either by clinicians or trained research coordinators.

JECS was approved by the institutional review board of the Ministry of the Environment and the ethics committees of all the participating institutions and is being conducted in accordance with the Declaration of Helsinki and other relevant regulations in Japan. Written informed consent was obtained from all the participants. As the present study used anonymized data, individual approval from the ethics committee was deemed unnecessary.

Target population, variables of interest, and outcomes {#Sec3}
------------------------------------------------------

The target population of the present study consisted of all women who participated in JECS and conceived by one of the following methods: 1) naturally; 2) using ovulation induction (OI) without ART; 3) conventional in vitro fertilization and embryo transfer (IVF-ET); or 4) intracytoplasmic sperm injection (ICSI). For the outcomes pertaining to fetuses/neonates, we analyzed only those delivered at 22 weeks or more of gestation. The variables of interest were conventional IVF-ET and ICSI. Women who conceived naturally served as the reference group. We also included women who conceived using OI without ART in order to estimate their risk level in case this might differ from that of natural pregnancies, given the former group's history of infertility and the effect of OI \[[@CR16], [@CR17], [@CR22]\].

Maternal complications and adverse outcomes included placenta previa, placental abruption, MAP, PIH, gestational diabetes, cesarean section, maternal blood transfusion, maternal admission to the ICU, and maternal death. Stillbirth (≥ 22 weeks of gestation), pre-term birth (\< 37 weeks of gestation), and low birth weight (\< 2500 g) were considered to be adverse fetal/neonatal outcomes. All of the maternal/perinatal complications and adverse outcomes were diagnosed following the protocol at each participating institution, which was presumably based on the relevant Japanese guidelines. Pregnancy-induced hypertension was defined as "hypertension (systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90 mmHg) observed from the 20^th^ week of gestation to 12 weeks postpartum with or without proteinuria (≥300 mg/day), not just as a continuing pre-existing condition" \[[@CR23]\]. Gestational diabetes was defined as a "glucose metabolism disorder occurring or recognized during pregnancy, excluding overt diabetes" \[[@CR24]\]. An oral glucose tolerance test with 75 g sugar was used for diagnosis, and the diagnostic criteria were blood glucose values of: 1) ≥92 mg/dL in a fasted state; 2) ≥180 mg/dL after one hour; or 3) ≥153 mg/dL after two hours.

Statistical analysis {#Sec4}
--------------------

First, we described the background characteristics of the participants who were included in the analysis, their pregnancy course, maternal and perinatal complications, and adverse outcomes by group (i.e., natural conception, OI without ART, conventional IVE-ET or ICSI). Next, the effect of each mode of conception on maternal/perinatal complications and adverse outcomes was assessed using logistic regression for maternal outcomes and generalized estimating equations (GEE) for fetal/neonatal outcomes, with women who conceived naturally serving as the reference group. The crude odds ratio (OR) and adjusted odds ratio (aOR) were calculated; adjusted covariates included maternal age, maternal body mass index (BMI) before pregnancy, maternal height, maternal weight before delivery, parity, prior cesarean section, pre-existing condition (e.g., chronic hypertension, hyperthyroidism, hypothyroidism, diabetes mellitus, autoimmune disease, heart disease, kidney disease, hepatitis, cerebral infarction, intracranial hemorrhage, epilepsy, blood disease, malignancy, psychiatric disorder, neurologic disease, thrombosis, and others), multiple pregnancies, fetal presentation, folic acid supplementation, maternal smoking during pregnancy, maternal drinking during pregnancy, maternal educational level, paternal smoking, paternal educational level, and household income. The variables included in the multivariate models as potential confounders were selected based on previous studies, biological plausibility, and their availability in the JECS data set \[[@CR25]--[@CR31]\]. We reported all crude ORs and aORs with the corresponding 95% confidence interval (CI). In order to improve the robustness of the analysis, we also conducted multiple imputation and compared the results with those from the model with case-wise deletion of missing data. The statistical analysis was conducted using the SAS software program (version 9.4; SAS Institute Inc., Cary, NC, USA).

Results {#Sec5}
=======

The final set of participants included in the main analysis consisted of women who conceived naturally (*N* = 90,506), by OI without ART (*N* = 3939), by conventional IVF-ET (*N* = 1476), and by ICSI (*N* = 1671). These pregnancies resulted in 96,860 fetuses/neonates in total delivered at 22 weeks or more of gestation, including live births and stillbirths, counting singletons and multiples, while excluding miscarriages/abortions before 22 weeks of gestation and cases with missing data on gestational age at birth. Figure [1](#Fig1){ref-type="fig"} shows the flow chart of the participants who were either included in the main analysis or excluded for failing to meet the inclusion criteria.Fig. 1Flow chart of participants in the analysis

Table [1](#Tab1){ref-type="table"} summarizes the background characteristics of the women who were included in the main analysis. Women who conceived by ART were more likely to be older, nulliparous, have a pre-existing condition, taking daily folic acid supplementation, non-smokers, have a higher education, and come from a wealthier household in contrast to women who conceived naturally. Table [2](#Tab2){ref-type="table"} shows the pregnancy and fetal/neonatal characteristics by mode of conception. Women who conceived by OI without ART had the highest proportion of multiple births among the four groups (4.9%). Table [3](#Tab3){ref-type="table"} shows the maternal/perinatal complications and adverse outcomes by mode of conception in all pregnancies, pregnancies with singletons, and pregnancies with multiples.Table 1Background characteristics of participants by mode of conceptionNatural conceptionOI without ARTConventional IVF-ETICSI*N* = 90,506*N* = 3939*N* = 1476*N* = 1671MedianIQRMedianIQRMedianIQRMedianIQRMaternal age (years)318336366366 Missing (N)73331417Maternal height (cm)158.08.0158.07.5158.78.0158.57.0 Missing (N)4772336Maternal BMI before pregnancy (kg/m^2^)20.63.520.63.720.73.420.73.3 Missing (N)1089411517Maternal weight before delivery (kg)62.310.662.111.162.410.661.810.5 Missing (N)30191585579N%N%N%N%Parity 033,76038.2229059.994966.0108968.1 134,93439.5133134.844731.146929.3 2 or more19,71222.32015.3422.9422.6 (Missing)21001173871Prior cesarean section No82,24290.9368093.5134691.2153091.6 Yes82009.12576.51308.81418.4 (Missing)64200Marital status Married85,78995.2391999.61474100.0166899.8 Single43044.8160.400.030.2 (Missing)413420Pre-existing maternal condition No74,96385.4308081.3108775.3124277.6 Yes12,85814.671018.735724.735922.4 (Missing)245413Folic acid supplementation No47,80353.0131033.347031.947628.5 A few times per month46105.11844.7382.6523.1 A few times per week14,12715.773518.725117.029317.6 Daily23,72126.3170643.471648.584750.8 (Missing)6952187Maternal smoking during pregnancy No85,15294.8386798.7145399.0164999.1 Yes46595.2511.3151.0150.9 (Missing)4401033Maternal drinking during pregnancy No81,03390.0357991.1136292.5152591.4 Yes903310.03508.91117.51438.6 (Missing)25121003842Maternal educational level Junior high/high school33,02637.590423.533523.335822.0 Vocational school/junior college36,49941.5186648.667346.877747.7 University/graduate school18,46921.0106927.843029.949430.3 (Missing)1902471523Paternal smoking No45,91651.8246463.397766.9114569.5 Yes42,68848.2142836.748433.150330.5 (Missing)31051053945Paternal educational level Junior high/high school39,60145.3122932.147533.150330.9 Vocational school/junior college19,68722.590223.527218.935121.6 University/graduate school28,11332.2170344.469048.077247.5 (Missing)843528393116Household income (×10,000 Japanese yen)  \< 20049566.0732.0171.2201.3  ≥ 200, \< 40029,34635.894926.027920.225816.6  ≥ 400, \< 60026,97932.9131936.148034.752133.5  ≥ 600, \< 80012,55415.374720.431823.039125.1  ≥ 800, \< 100050126.13289.016111.620413.1  ≥ 100032243.92406.61289.316110.4 (Missing)843528393116*ART* assisted reproductive technologies, *BMI* body mass index, *ICSI* intracytoplasmic sperm injection. *IQR* interquartile range, *IVF-ET* in vitro fertilization and embryo transfer, *OI* ovulation inductionProportions were calculated excluding cases with missing dataTable 2Pregnancy and fetal/neonatal characteristics by mode of conceptionNatural conceptionOI without ARTConventional IVT-ETICSIN%N%N%N%Pregnancies*N* = 90,506*N* = 3939*N* = 1476*N* = 1671 Singleton pregnancy88,87399.3370295.1140795.7158696.0 Multiple pregnancies6250.71894.9634.3664.0 (Missing)100848619Fetus/Neonate born ≥22 weeks*N* = 89,576*N* = 4067*N* = 1518*N* = 1699Number of fetuses Singletons88,33798.6368290.6139391.8157092.4 Multiples12091.43839.41258.21297.6 (Missing)30200Fetal presentation Cephalic85,33196.4372693.2134590.7151690.8 Non-cephalic31793.62736.81389.31539.2 (Missing)1066683530Sex of neonate Male45,94251.3206250.780553.085050.0 Female43,60848.7200349.371347.084950.0 (Missing)26200*ART* assisted reproductive technology, *ICSI* intracytoplasmic sperm injection, *ICU* intensive care unit, *IVF-ET* in vitro fertilization and embryo transfer, *OI* ovulation inductionProportions were calculated excluding cases with missing dataTable 3Maternal/perinatal complications and adverse outcomes by mode of conception in all pregnancies, pregnancies with singletons, and pregnancies with multiplesNatural conceptionOI without ARTConventional IVT-ETICSIN%N%N%N%All women and a fetus/neonate born ≥22 weeks Maternal outcomes*N* = 90,506*N* = 3939*N* = 1476*N* = 1671  Placenta previa4890.5220.6362.4301.8  Placental abruption3820.4190.580.5191.2  MAP1720.290.2171.2241.5  Gestational diabetes23042.61383.5765.2804.8  PIH26322.91774.51016.91076.5  Cesarean section16,43318.593324.256338.661737.8  Blood transfusion3770.4200.5362.4382.3  ICU admission1050.180.270.5150.9  Maternal death100000000 Fetal/neonatal outcomes*N* = 89,576*N* = 4067*N* = 1518*N* = 1699  Stillbirth2300.3170.4100.750.3  Preterm birth \< 37 w47685.342310.418412.118110.7  Low birth weight \< 2500 g79808.965116.024316.024514.4Women with a singleton pregnancy and singleton born ≥22 weeks Maternal outcomes*N* = 88,873*N* = 3702*N* = 1407*N* = 1586  Placenta previa4860.5200.5342.4281.8  Placental abruption3800.4180.580.6191.2  MAP1720.280.2171.2241.5  Gestational diabetes22712.61323.6725.1754.7  PIH25732.91654.5936.61026.4  Cesarean section15,91218.078021.250936.555835.6  Blood transfusion3680.4160.4332.4372.3  ICU admission970.150.170.5120.8  Maternal death100000000 Fetal/neonatal outcomes*N* = 88,337*N* = 3682*N* = 1393*N* = 1570  Stillbirth2160.280.280.640.3  Preterm birth41534.72115.71208.61197.6  Low birth weight \< 2500 g71418.137310.115911.415910.1Women with multiple pregnancies and multiples born ≥22 weeks Maternal outcomes*N* = 625*N* = 189*N* = 63*N* = 66  Placenta previa30.510.523.223.1  Placental abruption20.310.50000  MAP0010.50000  Gestational diabetes315.163.246.357.8  PIH579.4126.5812.757.8  Cesarean section51885.815181.25487.15992.2  Blood transfusion91.531.634.811.6  ICU admission81.331.60034.7  Maternal death00000000 Fetal/neonatal outcomes*N* = 1209*N* = 383*N* = 125*N* = 129  Stillbirth131.192.321.610.8  Preterm birth61350.721255.46451.26248.1  Low birth weight \< 2500 g83869.327872.88467.28666.7*ART* assisted reproductive technologies, *ICSI* intracytoplasmic sperm injection, *ICU* intensive care unit, *IVF-ET* in vitro fertilization and embryo transfer, *MAP* morbidly adherent placenta, *OI* ovulation induction, *PIH* pregnancy-induced hypertensionProportions were calculated excluding cases with missing data

The association between each mode of conception and maternal/perinatal complications and adverse outcomes was assessed using a logistic regression and GEE analysis, with women who conceived naturally serving as a reference (Table [4](#Tab4){ref-type="table"}). Pregnancies resulting from OI without ART did not have an increased risk of maternal/perinatal complications or adverse outcomes. Maternal death and stillbirth were not assessed because the number of cases was insufficient to calculate the aORs.Table 4Effect of mode of conception on maternal/perinatal complications and adverse outcomesLogistic regression with case-wise deletion of missing dataMultiple imputationCrude OR95% CIaOR95% CIaOR95% CIOI without ART Maternal outcomes^a^  Placenta previa0.760.431.310.620.351.090.850.551.32  Placental abruption1.330.822.181.330.802.191.130.711.81  MAP1.460.742.861.460.732.911.230.622.45  Gestational diabetes1.401.161.690.970.801.190.980.811.18  PIH1.551.301.841.100.911.321.110.941.31  Cesarean section1.411.291.531.120.991.261.080.971.21  Blood transfusion1.350.832.211.030.621.710.940.591.5  ICU admission2.161.044.461.290.602.791.070.492.3 Fetal/neonatal outcomes^b^  Preterm birth1.931.712.181.050.091.241.010.861.18  Low birth weight1.881.702.071.040.931.191.040.931.17Conventional IVT-ET Maternal outcomes^a^  Placenta previa4.683.226.822.901.944.342.861.994.12  Placental abruption1.030.432.500.910.372.261.080.532.22  MAP6.884.0911.586.853.8812.135.742.9311.2  Gestational diabetes1.881.452.450.990.751.311.130.881.45  PIH2.431.943.051.401.101.781.411.131.76  Cesarean section2.692.393.021.851.582.171.91.642.19  Blood transfusion6.184.209.093.852.525.883.572.455.21  ICU admission4.982.3010.802.581.116.012.040.894.66 Fetal/neonatal outcomes^b^  Preterm birth2.592.183.081.421.131.781.361.111.66  Low birth weight1.901.632.220.940.761.151.010.851.2ICSI Maternal outcomes^a^  Placenta previa3.372.225.112.011.293.132.021.363.01  Placental abruption2.441.404.262.161.203.882.351.443.82  MAP7.414.5712.007.814.5613.387.864.5613.5  Gestational diabetes1.851.432.380.970.741.271.060.831.35  PIH2.161.732.711.250.981.601.341.071.67  Cesarean section2.752.463.071.891.622.191.821.592.09  Blood transfusion5.984.118.693.762.495.663.432.374.96  ICU admission7.113.7813.363.451.687.063.872.077.24 Fetal/neonatal outcomes^b^  Preterm birth2.331.962.771.311.051.641.210.991.47  Low birth weight1.781.532.070.870.721.060.890.741.06*aOR* adjusted odds ratio, *ART* assisted reproductive technologies, *CI* confidence intervals, *ICSI* intracytoplasmic sperm injection, *ICU* intensive care unit, *IVF-ET* in vitro fertilization and embryo transfer, *MAP* morbidly adherent placenta, *OI* ovulation induction, *OR* odds ratio, *PIH* pregnancy-induced hypertensionWomen who conceived naturally served as the reference groupAdjusted odds ratios were calculated by controlling for maternal age, maternal body mass index (BMI) before pregnancy, maternal height, maternal weight before delivery, parity, prior cesarean section, pre-existing maternal conditions, multiple pregnancies, fetal presentation, folic acid supplementation, maternal smoking during pregnancy, maternal drinking during pregnancy, maternal educational level, paternal smoking, paternal educational level, and household income^a^logistic regression; ^b^generalized estimating equations (GEE)

Women who conceived by conventional IVF-ET were at higher risk of placenta previa (aOR 2.90 \[95% CI 1.94, 4.34\]), MAP (aOR 6.85 \[95% CI 3.88, 12.13\]), and PIH (aOR 1.40 \[95% CI 1.10, 1.78\]) than those who conceived naturally. Women who conceived by ICSI had a higher risk of placental abruption (aOR 2.16 \[95% CI 1.20, 3.88\]) as well as placenta previa (aOR 2.01 \[95% CI 1.29, 3.13\]), MAP (aOR 7.81 \[95% CI 4.56, 13.38\]), and marginally significant PIH (aOR 1.25 \[95% CI 0.98, 1.60\]). Furthermore, women who conceived by ART were more likely to have a cesarean section and had a significantly higher risk of blood transfusion (conventional IVF-ET: aOR 3.85 \[95% CI 2.52, 5.88\]; ICSI: aOR 3.76 \[95% CI 2.49, 5.66\]) and ICU admission (conventional IVF-ET: aOR 2.58 \[95% CI 1.11, 6.01\]; ICSI: aOR 3.45 \[95% CI 1.68, 7.06\]) even after controlling for potential confounders. Neonates born after ART were at higher risk of preterm birth (conventional IVF-ET: aOR 1.42 \[95% CI 1.13, 1.78\]; ICSI: aOR 1.31 \[95% CI 1.05, 1.64\]) compared to those conceived naturally.

We also performed multiple imputation and compared the results with those from the logistic regression model with case-wise deletion of missing data (Table [4](#Tab4){ref-type="table"}). The estimated effects of the variables of interest were similar in terms of their direction and magnitude.

Discussion {#Sec6}
==========

Compared with women who conceived naturally, those who conceived by conventional IVF-ET were at higher risk of placenta previa, MAP, and PIH whereas those who conceived by ICSI had a higher risk of placental abruption in addition to the above. Women who conceived by ART had a significantly higher risk of blood transfusion and ICU admission even after controlling for maternal age, pre-existing condition, and other potential confounders. Neonates conceived by ART were at higher risk of preterm birth.

The increased risk of maternal and perinatal complications observed in the present study were largely consistent with the findings of previous studies \[[@CR6]--[@CR10], [@CR14]--[@CR16]\]. Among these complications, the risk of MAP was conspicuous, with an aOR of 6.85 for conventional IVF-ET and 7.81 for ICSI. More than 1% of women who conceived by ART had MAP; however, this figure should be interpreted with caution as the diagnoses were made clinically irrespective of pathological examination in JECS. The relationship between IVF pregnancies and MAP was first reported by Esh-Broder, et al. in 2011 \[[@CR10]\]. MAP is one of the major causes of catastrophic outcomes in obstetrics, and placenta previa and previous cesarean section are known risk factors of MAP \[[@CR32], [@CR33]\]. Prenatal diagnosis is crucial for appropriate management, and ultrasound examination and magnetic resonance imaging are used especially for women with risk factors \[[@CR34], [@CR35]\]. However, prenatal diagnosis is not always possible. Given the observed relationship between ART and MAP, obstetricians should consider women who conceived by ART as a high risk group for MAP regardless of their prenatal diagnosis. In addition to the incidence of MAP, the observed incidence of placenta previa was also high among ART pregnancies (2.4% for conventional IVF, 1.8% for ICSI).

With regard to life-threatening maternal conditions, studies such as the one by Belanoff et al. have reported a higher risk of severe maternal morbidity in women who conceived using ART \[[@CR17]--[@CR19]\]. Cromi et al. reported on the risk of a peripartum hysterectomy in pregnancies resulting from ART in 2016, arguing that such pregnancies should be managed as "high risk" \[[@CR20]\]. In our study, more than 2% of women who conceived by ART received a blood transfusion. We realize that the incidence of these complications may be overestimated (or underestimated) depending upon the participants' characteristics, given that JECS is not completely population-based. However, according to the profile paper of JECS, characteristics of the women and children who participated in JECS appeared to be comparable to those reported in Japan's Vital Statistics Survey \[[@CR36]\]. Hence, the observed higher risk of blood transfusion (conventional IVF-ET: aOR 3.85, ICSI: aOR 3.76) and ICU admission (conventional IVF-ET: aOR 2.58, ICSI: aOR 3.45) in ART pregnancies is deemed to be reliable.

In the present study, we estimated the risk levels of women who conceived using OI without ART separately from those of women who conceived naturally, considering the possibility that they might differ given the former's history of infertility and the effect of OI. Although univariate analysis demonstrated an increased risk for some of the maternal/perinatal complications and adverse outcomes, none reached statistical significance after controlling for potential confounders.

The present study has several strengths. First and foremost, JECS is the largest birth cohort in the country and collects wide-ranging, in-depth information from participants and their medical records. This enabled us to control for various potential confounders including participants' socio-economic status. In addition, the present study included blood transfusion and ICU admission as maternal adverse outcomes, unlike previous studies.

Nonetheless, the present study has several limitations. First, JECS was not designed to cover all expecting mothers during the recruitment period or apply complete random sampling (JECS aimed to cover 50% of the births in each study area \[[@CR21]\].) Therefore, bias may have entered into the selection of the participants, thus leading to overestimation or underestimation of the incidence of maternal/perinatal complications and adverse outcomes. As mentioned above, however, the JECS profile paper suggested that the characteristics of the study participants were comparable to those collected in the national survey \[[@CR36]\]. Second, the data pertaining to each woman's mode of conception were self-reported, potentially jeopardizing their reliability. Furthermore, detailed data on the drugs and techniques used for OI or ART (e.g., fresh or frozen embryo transfer, blastocyst or cleavage stage embryo transfer) were not assessed. Third, data on some of the adverse outcomes, such as hysterectomy, were not collected in JECS. The number of maternal deaths and stillbirths was limited; hence, these figures were not included in the main analysis. Last, the diagnoses of maternal and perinatal complications were made at each participating facility, and subsequent interventions (e.g., blood transfusion and ICU admission) were conducted based on institutional protocols; hence, there may have been some variation in the diagnostic criteria and/or management strategies.

Conclusions {#Sec7}
===========

Women who conceived by ART were at higher risk of maternal and perinatal complications necessitating advanced/emergency obstetric care, such as a blood transfusion or ICU admission. Obstetricians should be aware of the increased risk of adverse maternal outcomes among women who conceived by ART.
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